NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $17.60 +0.46 (+2.68%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Entrada Therapeutics Stock (NASDAQ:TRDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$17.16▼$17.8650-Day Range$13.65▼$17.8352-Week Range$10.75▼$18.17Volume83,564 shsAverage Volume101,352 shsMarket Capitalization$654.72 millionP/E Ratio5.95Dividend YieldN/APrice Target$21.50Consensus RatingBuy Company OverviewEntrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More… Musk Says ‘Dollar Will Be Worth Nothing…’ (Ad)Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… Entrada Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks48th Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 619th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from $0.68 to ($3.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is 5.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is 5.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 116.10.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.64% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 19.12%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.64% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 19.12%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News SentimentN/A News SentimentEntrada Therapeutics has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Entrada Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for TRDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $155,947.00 in company stock.Percentage Held by InsidersOnly 7.59% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Stock News HeadlinesEntrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 600 SharesOctober 19, 2024 | insidertrades.comHere's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price StrengthOctober 15, 2024 | finance.yahoo.comMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…November 2, 2024 | Crypto 101 Media (Ad)Entrada Therapeutics (NASDAQ:TRDA) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comEntrada Therapeutics Presents Data Supporting Advancement Of Duchenne FranchiseOctober 9, 2024 | markets.businessinsider.comEntrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle SocietyOctober 9, 2024 | globenewswire.comEntrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and DevelopmentSeptember 24, 2024 | globenewswire.comāshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of DirectorsSeptember 17, 2024 | finance.yahoo.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $15.09 at the beginning of 2024. Since then, TRDA shares have increased by 16.6% and is now trading at $17.60. View the best growth stocks for 2024 here. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) released its quarterly earnings results on Tuesday, August, 13th. The company reported $1.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.90. The company had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55 million. Entrada Therapeutics had a net margin of 43.63% and a trailing twelve-month return on equity of 35.16%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' top institutional investors include BayBridge Capital Group LLC (0.09%), Allspring Global Investments Holdings LLC (0.06%), SG Americas Securities LLC (0.03%) and US Bancorp DE (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth, Peter S Kim, Nerissa Kreher and John F Crowley. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/13/2024Today11/01/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$21.50 High Stock Price Target$25.00 Low Stock Price Target$18.00 Potential Upside/Downside+22.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$2.96 Trailing P/E Ratio5.95 Forward P/E Ratio25.88 P/E GrowthN/ANet Income$-6,680,000.00 Net Margins43.63% Pretax Margin46.11% Return on Equity35.16% Return on Assets20.41% Debt Debt-to-Equity RatioN/A Current Ratio5.70 Quick Ratio5.70 Sales & Book Value Annual Sales$129.01 million Price / Sales5.07 Cash FlowN/A Price / Cash FlowN/A Book Value$7.26 per share Price / Book2.42Miscellaneous Outstanding Shares37,200,000Free Float34,377,000Market Cap$654.72 million OptionableOptionable Beta-0.25 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TRDA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.